HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Industrial Cannabis/Industrial Hemp

617.047

-3.604-0.58%

Number of Gainers:3

Number of Losers:2

Number of Flat:2

PE:- -

High:633.990

Open:622.897

Low:612.628

Close:620.651

Volume:58.40M

Turnover:75.39M

Market Cap:25.13B

Float Cap:25.13B

Loading ...

Evergreen Products Group to Seek Shareholder Approval for New Articles of Association on May 15, 2026

Sihuan Pharmaceutical unit publishes BRIGHT-2 Phase 3 results for biloxcilib plus fulvestrant in JAMA Oncology

Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer

MEILLEUREHEALTH (02327) Proposes Adoption of 2026 Share Award Scheme

Musk Officially Launches Terafab Project Targeting Annual Production of 1 Terawatt Computing Power; ZIJIN MINING Reports 61.55% Net Profit Growth for 2025

Xuanzhu Biopharmaceutical completes enrollment of 500 patients in China Phase 3 trial of anaprazole sodium enteric-coated tablets for reflux esophagitis

Xuanzhu Biopharmaceutical completes enrollment of 500 subjects in China Phase III reflux esophagitis trial of anaprazole sodium tablets

China Carbon Neutral Development Group converts HKD 57.66 million debt into convertible bonds and raises HKD 48 million in share subscription proceeds

BRIEF-Ynby International Discloses Proposed On-Market Share Buy-Back

YNBY INTL (00030) Plans Share Buyback in Open Market

YNBY International - Formally Resolved to Authorize Management to Utilize Buy-Back Mandate

THOMSON REUTERS

YNBY International - Proposed on-Market Share Buy-Back

THOMSON REUTERS

YNBY International - Maximum Fund for Share Repurchase Set at HK$39 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1600/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1600","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1600\",,,,,undefined,":{"symbol":"BK1600","market":"HK","secType":"PLATE","nameCN":"Industrial Cannabis/Industrial Hemp","latestPrice":617.0467,"timestamp":1774944503193,"preClose":620.6512,"halted":0,"volume":58396727,"delay":0,"changeRate":-0.005808,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-3.604492,"latestTime":"03-31 16:00:00","open":622.89667,"high":633.9902,"low":612.6283,"amount":75393361,"amplitude":0.034418,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775007000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774920600000,1774929600000],[1774933200000,1774944000000]],"pbRate":2.093962,"peRate":226.152114,"turnoverRate":0.001934,"increases":3,"decrements":2,"flats":2,"marketCap":25133430936,"floatMarketCap":25133430936},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1600\",,,,,undefined,":{"symbol":"BK1600","high":633.9902,"amplitude":0.034418,"preClose":620.6512,"low":612.6283,"pbRate":"2.093962","latestPrice":617.0467,"volume":58396727,"delay":0,"open":622.89667,"prevYearClose":572.4504,"prevWeekClose":620.545,"prevMonthClose":657.154,"prevQuarterClose":572.45,"fiveDayClose":604.864,"twentyDayClose":619.232,"sixtyDayClose":572.45,"secType":"PLATE","market":"HK","turnoverRate":0.001934,"peRate":226.152114,"marketCap":25133430936,"floatMarketCap":25133430936,"timestamp":1774944503193,"nameCN":"Industrial Cannabis/Industrial Hemp"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1600\",,,,undefined,":{"bkCode":"BK1600","up":3,"down":2,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1600\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621060064","title":"Evergreen Products Group to Seek Shareholder Approval for New Articles of Association on May 15, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621060064","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621060064?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:38","pubTimestamp":1774359508,"startTime":"0","endTime":"0","summary":"Evergreen Products Group announced proposed amendments to its existing memorandum and articles of association and the adoption of a fifth amended and restated memorandum and articles of association.The changes are intended to align the company’s articles with updated listing rule requirements, including measures related to a paperless listing regime.Planned updates include enabling shareholder instructions by electronic means, electronic payment of corporate action proceeds including dividends, and electronic voting at general meetings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evergreen Products Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL2VDb4z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1668664300.SGD","LU1019634622.SGD","LU0106831901.USD","LU0171281750.USD","LU0898667661.SGD","IE0008369823.USD","LU0516423174.USD","LU2293690249.USD","IE0034235071.USD","LU1015430645.USD","LU0831103253.SGD","LU0516422440.USD","LU0149721374.USD","LU0572939691.SGD","LU0634319403.HKD","LU0348735423.USD","LU1481107354.HKD","LU0307460666.USD","BK1600","HSBA.UK","LU2091194634.USD","LU2293690082.USD","LU1023061473.USD","LU0171293334.USD","LU1153584641.USD","LU0588546209.SGD","LU0575583348.USD","LU0264606111.USD","LU0164880469.USD","BK1585","LU2114397693.USD","LU2539964713.USD","LU0964806797.USD","LU0215105999.USD","LU1019632923.USD","LU0516423091.SGD","LU0540923850.HKD","LU0516422366.SGD","LU1051770623.HKD","LU2449936058.SGD","LU0572940350.SGD","LU1023061713.HKD","BK5152","01962","LU1003076772.USD","BK1207","LU1046234339.USD","LU0516422952.EUR","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621306116","title":"Sihuan Pharmaceutical unit publishes BRIGHT-2 Phase 3 results for biloxcilib plus fulvestrant in JAMA Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2621306116","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621306116?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:48","pubTimestamp":1774352903,"startTime":"0","endTime":"0","summary":"Sihuan said its majority-owned unit Xuanzhu Biopharma published final Phase 3 BRIGHT-2 results for CDK2/4/6 inhibitor piruoxib in combination with fulvestrant in JAMA Oncology.The company stated the study reported a median progression-free survival of 14.7 months versus 7.3 months, with a 46% reduction in risk of disease progression or death.Sihuan said the treatment achieved an objective response rate of 50.3% versus 16.7% in patients with measurable disease.The company said the drug has received China approvals for use in HR+/HER2- advanced or metastatic breast cancer in combination with fulvestrant, as monotherapy, and in combination with an aromatase inhibitor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Ho","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL3kmNYg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1593","BK1191","00460","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621069888","title":"Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069888","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069888?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:06","pubTimestamp":1774350387,"startTime":"0","endTime":"0","summary":"Xuanzhu reported final Phase 3 BRIGHT-2 results for its breast cancer product bireociclib in combination with fulvestrant, with the analysis published in JAMA Oncology.The company said median progression-free survival was 14.7 months versus 7.3 months for placebo plus fulvestrant, with a 46% reduction in risk of progression or death .In patients with measurable disease, the objective response rate was 50.3% versus 16.7% for the control group.Xuanzhu said bireociclib has been approved in China for use with fulvestrant in HR+/HER2- advanced or metastatic breast cancer after progression on prior endocrine therapy, positioning it for broader clinical adoption.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL20tgp6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191","BK1600","BK1515","00460","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138076436","title":"MEILLEUREHEALTH (02327) Proposes Adoption of 2026 Share Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1138076436","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138076436?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:06","pubTimestamp":1774346785,"startTime":"0","endTime":"0","summary":"MEILLEUREHEALTH (02327) announced that the board of directors has recommended the adoption of a 2026 share award scheme. The proposed scheme will have a term of ten years from the date of adoption,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02327","BK1124","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172909581","title":"Musk Officially Launches Terafab Project Targeting Annual Production of 1 Terawatt Computing Power; ZIJIN MINING Reports 61.55% Net Profit Growth for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1172909581","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172909581?lang=en_us&edition=fundamental","pubTime":"2026-03-23 07:33","pubTimestamp":1774222403,"startTime":"0","endTime":"0","summary":"Elon Musk has officially launched the Terafab project, which aims to achieve an annual production capacity of 1 terawatt of computing power, with deployment primarily planned for space. SpaceX and...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a9cc1a3504381c7d0d6994d21d88e8a3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0244354667.USD","LU0634319403.HKD","LU2360106780.USD","TLA","TSDD","LU0588546209.SGD","LU0348816934.USD","LU1064131342.USD","LU2249611893.SGD","LU0823411888.USD","IE00BK4W5L77.USD","LU0466842654.USD","LU2471134952.CNY","LU2543165471.USD","LU2756315664.SGD","LU0531971595.HKD","LU0737861699.HKD","LU2023250330.USD","LU2226246903.HKD","LU0348723411.USD","LU0964807845.USD","LU2417539215.USD","LU0868486357.SGD","TSLZ","HK0000500386.USD","BK1610","LU0165289439.USD","CRSH","LU0572944931.SGD","LU1720051108.HKD","SG9999015952.SGD","02899","BK1116","LU1719994722.HKD","LU2097828631.EUR","BK4099","LU0345769128.USD","HK0000252152.HKD","LU1914381329.SGD","LU2213484517.USD","LU0943347566.SGD","LU1852331112.SGD","LU0456854461.SGD","TSLR","LU0918141887.USD","LU1504937902.USD","LU0181495838.USD","LU0266512127.USD","LU0516422366.SGD","LU0540923850.HKD","LU0327786744.USD","TSLY","LU1813983027.USD","LU2602419157.SGD","LU1961090484.USD","LU2462157665.USD","SGXZ49509284.SGD","LU0823414478.USD","LU0345769631.USD","LU1770034418.SGD","LU2097828805.USD","LU3063872942.SGD","LU2063271972.USD","LU2039709279.SGD","LU0463099449.HKD","HK0000320223.HKD","TSL","LU0077335932.USD","LU1769817179.HKD","LU1282648689.USD","LU0287142896.SGD","LU2264538146.SGD","IE00BJLML261.HKD","TSLG","LU0210536198.USD","SG9999015978.USD","LU2097828714.EUR","LU0228659784.USD","BK1528","LU0708995401.HKD","BK4574","LU0140636845.USD","LU0323591593.USD","LU0719512351.SGD","LU0326950275.SGD","BK0028","LU1064131003.USD","LU1255011170.USD","LU1366192091.USD","LU0345770993.USD","BK1515","LU1066053197.SGD","LU1251922891.USD","BK0183","LU0871576103.HKD","BK1238","LU0561508036.HKD","LU0198837287.USD","IE0034235303.USD","LU2236285917.USD","LU2420271590.USD","LU0328353924.USD","LU2580892789.USD","LU2097828474.EUR","BK4555","LU0082770016.USD","LU0164865239.USD","LU0307460666.USD","BK0127","LU0469268626.HKD","LU0043850808.USD","LU0329678170.USD","LU2148510915.USD","IE00B1BXHZ80.USD","LU0164880469.USD","LU1831875114.USD","LU0651947912.USD","TSLQ","LU0516422440.USD","LU0431992006.USD","LU0048580855.USD","BK1521","BK4581","HK0000306701.USD","TSLW","LU1481107354.HKD","LU1303224171.USD","LU1808992512.USD","LU0314109678.HKD","LU1066051498.USD","TSLT","LU1232071149.USD","LU0097036916.USD","LU1548497426.USD","LU2896262040.SGD","LU0082616367.USD","BK4533","LU1551013342.USD","LU1655091616.SGD","LU0096374516.USD","LU0516423174.USD","LU0348766576.USD","IE00B1XK9C88.USD","LU0106252389.USD","IE00BK4W5M84.HKD","LU1066051811.HKD","LU2471134796.USD","BK4548","BK1592","LU0828237940.HKD","SGXZ86797644.SGD","LU2750360997.AUD","LU2289578879.USD","LU0918141705.HKD","LU1720051017.SGD","BK4543","BK0242","LU0417516902.SGD","SG9999004220.SGD","TSLI","BK0196","LU0820561909.HKD","LU2097828557.USD","LU0797268264.HKD","80883","BK1544","LU2756315318.SGD","LU0228367735.SGD","LU1769817096.USD","BK4551","BK4527","LU1515016050.SGD","HK0000252160.HKD","LU1720050803.USD","LU0234572021.USD","TESL","LU0672654240.SGD","LU0211977185.USD","SG9999015986.USD","TSLP","LU1145028129.USD","BK1600","LU0345770308.USD","LU1429558221.USD","BK1191","LU0266512473.USD","LU0820561818.USD","LU0053666078.USD","LU0348827113.USD","LU0593848301.USD","LU1674673691.USD","LU0039217434.USD","BK4592","TSYY","LU1267930730.SGD","LU2399975544.HKD","LU0516422952.EUR","LU0651946864.USD","LU0316494557.USD","LU1551013425.SGD","LU0737861772.HKD","LU2290526834.HKD","LU2580892862.HKD","HK0000306685.HKD","LU1051769294.HKD","LU2108987350.USD","BK0012","BK4516","BK1198","LU1328277881.USD","LU2750360641.GBP","LU2456880835.USD","BK0188","LU0049853897.USD","LU0164939612.USD","LU0370786039.SGD","LU2213496289.HKD","IE00B19Z9505.USD","BK4550","LU1188198961.HKD","LU1997244956.HKD","IE00BSNM7G36.USD","UFO","LU0828237510.HKD","LU1979443071.USD","BK4588","LU0820562030.AUD","BK1505","LU1066051225.USD","SG9999002463.SGD","LU2087621335.USD","LU2326559502.SGD","LU1435385759.SGD","BK0077","LU0348735423.USD","LU2495084118.USD","LU2471134879.HKD","LU0689472784.USD","LU1048596156.SGD","LU1861215975.USD","LU1997245177.USD","TSLL","LU1861559042.SGD","TSLS","LU1778281490.HKD","HK0000320264.USD","SGXZ81163826.USD","BK4511","LU0348825331.USD","LU1224709979.USD","BK4612","LU0056508442.USD","BK1594","TSII","IE00BWXC8680.SGD","LU0417516738.SGD","LU0886674414.USD","IE00B19Z8X17.USD","LU1629891620.HKD","LU0082770016.SGD","LU0348814723.USD","LU1674673428.USD","LU0163747925.USD","LU0173614495.USD","LU0821914370.USD","LU1997245094.SGD","TSLO","LU0345780281.USD","SGXZ62798434.SGD","07766","BK1589","LU0149721374.USD","LU1861220033.SGD","LU0620787316.HKD","BK4604","LU1064130708.USD","IE00B19Z8W00.USD","IE0032431581.USD","LU0109391861.USD","LU1839511570.USD","LU0979878070.USD","BK4598","LU1242518931.SGD","LU1794554557.SGD","LU0516423091.SGD","BK4585","LU1051768304.USD","LU0329678337.USD","LU1861558580.USD","LU2471134523.USD","LU2357305700.SGD","LU0348767384.USD","LU2360107168.USD","LU1934453819.USD","LU0320765059.SGD","LU1105468828.SGD","TSLA","BK1593","BK4534","LU1242518857.USD","601899","SG9999015945.SGD","BK0015","LU0061477393.USD","TEST","LU0345780521.USD","LU1988902786.USD","LU2403377893.USD","LU2250418816.HKD","LU0234570918.USD","ZIJMY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621714840","title":"Xuanzhu Biopharmaceutical completes enrollment of 500 patients in China Phase 3 trial of anaprazole sodium enteric-coated tablets for reflux esophagitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2621714840","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621714840?lang=en_us&edition=fundamental","pubTime":"2026-03-22 18:08","pubTimestamp":1774174088,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical completes enrollment of 500 patients in China Phase 3 trial of anaprazole sodium enteric-coated tablets for reflux esophagitis. Xuanzhu reported full enrollment of 500 adults in a China Phase 3 trial of its product Anaprazole Sodium enteric-coated tablets  for reflux esophagitis.The trial milestone positions the program for potential expansion beyond Anaprazole’s existing China approval for duodenal ulcer treatment.Completion of enrollment may support near-term differentiation in the domestic reflux esophagitis market by advancing a locally developed therapy through late-stage development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to g","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nNDL6JMbm8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1600","00460","BK1191","BK1593","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621714823","title":"Xuanzhu Biopharmaceutical completes enrollment of 500 subjects in China Phase III reflux esophagitis trial of anaprazole sodium tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2621714823","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621714823?lang=en_us&edition=fundamental","pubTime":"2026-03-22 18:08","pubTimestamp":1774174083,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical completes enrollment of 500 subjects in China Phase III reflux esophagitis trial of anaprazole sodium tablets. Xuanzhu Biopharma reported completion of enrollment of 500 subjects in a China Phase III trial of anaprazole sodium enteric-coated tablets  for adult reflux esophagitis.The pivotal study is multi-center, randomized, double-blind, double-dummy, and active-controlled.The primary endpoint is endoscopic healing rate within 8 weeks of treatment.Secondary endpoints include endoscopic healing rate at week 4 and symptom changes at week 4 and week 8.No trial results were reported in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original conten","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nNDL8162Qw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1600","BK1515","02575","BK1593","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620781685","title":"China Carbon Neutral Development Group converts HKD 57.66 million debt into convertible bonds and raises HKD 48 million in share subscription proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2620781685","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620781685?lang=en_us&edition=fundamental","pubTime":"2026-03-20 17:18","pubTimestamp":1773998332,"startTime":"0","endTime":"0","summary":"China Carbon Neutral Development Group converts HKD 57.66 million debt into convertible bonds and raises HKD 48 million in share subscription proceeds. China Carbon Neutral said it obtained regulatory approval to convert about HKD 57.66 million of debt owed to two creditors into convertible bonds.The company issued 32 million new shares at HKD 1.5 per share, completing the subscription and raising about HKD 48 million in net proceeds.As of 28 February 2026, it had used HKD 11.34 million for daily operations and HKD 4.04 million for debt repayment from the subscription proceeds.The company said it had completed several carbon coin transactions at prices of USD 30 to USD 40 per ton.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDLbMFF57:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1594","BK1144","BK1600","BK1148","01372"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620230508","title":"BRIEF-Ynby International Discloses Proposed On-Market Share Buy-Back","url":"https://stock-news.laohu8.com/highlight/detail?id=2620230508","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620230508?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:22","pubTimestamp":1773832936,"startTime":"0","endTime":"0","summary":"BRIEF-Ynby International Discloses Proposed On-Market Share Buy-BackMarch 18  - YNBY International Ltd 0030.HK:PROPOSED ON-MARKET SHARE BUY-BACKFORMALLY RESOLVED TO AUTHORIZE MANAGEMENT TO UTILIZE BUY-BACK MANDATEMAXIMUM FUND FOR SHARE REPURCHASE SET AT HK$39 MILLIONFurther company coverage: 0030.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4050X1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1121","BK1600","00030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128127776","title":"YNBY INTL (00030) Plans Share Buyback in Open Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1128127776","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128127776?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:07","pubTimestamp":1773828470,"startTime":"0","endTime":"0","summary":"YNBY INTL (00030) announced that the company's board of directors has obtained shareholder approval at the Annual General Meeting held on May 16, 2025. This approval authorizes the board to...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","00030","BK1121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620267231","title":"YNBY International - Formally Resolved to Authorize Management to Utilize Buy-Back Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=2620267231","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620267231?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:01","pubTimestamp":1773828063,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4050X1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["00030","BK1600","BK1121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620231210","title":"YNBY International -  Proposed on-Market Share Buy-Back","url":"https://stock-news.laohu8.com/highlight/detail?id=2620231210","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620231210?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:01","pubTimestamp":1773828063,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4050X1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1600","BK1121","00030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620207231","title":"YNBY International - Maximum Fund for Share Repurchase Set at HK$39 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2620207231","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620207231?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:01","pubTimestamp":1773828063,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4050X1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1121","BK1600","00030"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":33,"code":"91000000","status":"200"}]}}